Volume 151, Issue 2, Pages 340-357 (February 2017) Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD  Fernando J. Martinez, MD, FCCP, Klaus F. Rabe, MD, PhD, Gary T. Ferguson, MD, FCCP, Leonardo M. Fabbri, MD, FCCP, Stephen Rennard, MD, FCCP, Gregory J. Feldman, MD, Sanjay Sethi, MD, Selwyn Spangenthal, MD, Gregory M. Gottschlich, MD, Roberto Rodriguez-Roisin, MD, PhD, FCCP, Samir Arora, MD, Thomas M. Siler, MD, FCCP, Shahid Siddiqui, MD, MHSA, Patrick Darken, PhD, Tracy Fischer, PharmD, Andrea Maes, PhD, Michael Golden, MS, Chad Orevillo, MPH, Colin Reisner, MD, FCCP  CHEST  Volume 151, Issue 2, Pages 340-357 (February 2017) DOI: 10.1016/j.chest.2016.11.028 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Patient disposition diagrams. FF = formoterol fumarate 9.6 μg; GFF = glycopyrrolate/formoterol fumarate 18/9.6 μg; GP = glycopyrrolate 18 μg; ITT = intent to treat; MDI = metered dose inhaler. CHEST 2017 151, 340-357DOI: (10.1016/j.chest.2016.11.028) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Study design. HFA = hydrofluoroalkane. See Figure 1 legend for expansion of other abbreviations. CHEST 2017 151, 340-357DOI: (10.1016/j.chest.2016.11.028) Copyright © 2016 The Authors Terms and Conditions

Figure 3 Mean change (± SE) from baseline in trough morning predose FEV1 over 24 weeks by treatment arm for each study (ITT population). See Figure 1 legend for expansion of abbreviations. CHEST 2017 151, 340-357DOI: (10.1016/j.chest.2016.11.028) Copyright © 2016 The Authors Terms and Conditions

Figure 4 Mean change (± SE) from baseline in peak FEV1 within 2 hours postdose over 24 weeks by treatment arm for each study (ITT population). See Figure 1 legend for expansion of abbreviations. CHEST 2017 151, 340-357DOI: (10.1016/j.chest.2016.11.028) Copyright © 2016 The Authors Terms and Conditions